AbbVie Inc. (ABBV)
Health Care20 articles
Price chart
Why is ABBV moving today?
+0.6%ABBV is +0.6% today, inside the ordinary range for a session (under 3%). No stories about it reached the feed in the last 24 hours.
What this does not prove. A story on the same day is evidence of timing, not of cause: it explains a move only if it accounts for the size and the direction, and most single-stock moves carry a sector or index component too. Nothing here is a forecast.
Source: Yahoo Finance - quote as of 13 hours ago
AbbVie Inc. (ABBV) overview
AbbVie is a research-based pharmaceutical company with a portfolio spanning immunology, oncology, and neuroscience.
ABBV is a member of the S&P 500. It sits in the Health Care sector. That sector covers pharmaceutical, biotech, device and managed-care companies.
AbbVie Inc. trades on the NYSE under the ticker symbol ABBV. The most recent market data puts the share price at about $283.40. That is up 0.59% on the session. At that price the company is worth roughly $500.80B.
Over the past 52 weeks, ABBV has traded between $190.75 and $291.33. Shares change hands at a trailing price-to-earnings (P/E) ratio of about 77.4. The P/E ratio sets the share price against a year of earnings. A higher number means the market is paying more for each dollar the company earns. ABBV also pays a dividend. It yields around 2.44% at the current price.
Key statistics
Source: Yahoo Finance - quote as of 13 hours ago
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch ABBV
ABBV is one of the larger names in the Health Care sector, so investors follow it closely. It tends to move with the rest of the sector. This page sums up each ABBV story as it breaks, and tags it bullish, bearish or neutral.
Size matters here as well. The S&P 500 is weighted by market value. ABBV is large enough that its own share price nudges the whole index. So it is worth watching even for investors who only hold index funds.
What moves ABBV
- Earnings. ABBV reports results four times a year. A surprise against the estimate tends to move the stock that day.
- Analyst calls. Upgrades, downgrades and new price targets change what the market expects from ABBV.
- Sector news. Health Care stocks often move together, so a rival's news can move ABBV too.
- Index weight. ABBV is big enough to move the S&P 500 on its own.
Market Mood
Latest ABBV news
AbbVie (ABBV) Rinvoq Receives EU Approval for Juvenile Arthritis
AbbVie’s drug Rinvoq received approval from the European Commission for the treatment of juvenile idiopathic arthritis in patients aged two and older. This approval expands the indications for Rinvoq, which is already approved for adults with certain forms of arthritis. The decision is expected to impact AbbVie's revenue sources positively by broadening the market for this medication. This matters for investors as it signals potential growth in sales for AbbVie (ABBV) through increased patient enrollment and treatment opportunities.
Read More: AbbVie (ABBV) Rinvoq Receives EU Approval for Juvenile Arthritis
AbbVie (ABBV) Qulipta Achieves Clinical Win for Menstrual Migraine
AbbVie (NYSE: ABBV) recently announced positive Phase 3 trial results for Qulipta, a migraine treatment, showing significant reductions in migraine days during the perimenstrual period compared to a placebo. Qulipta also met all secondary endpoints without introducing new safety signals. This success may lead to a label expansion, with an estimated market opportunity of over nine million adult patients in the U.S. alone for menstrual migraines. The ability of Qulipta to penetrate this market will depend on health insurance coverage and patient's perceptions of their migraine severity.
Read More: AbbVie (ABBV) Qulipta Achieves Clinical Win for Menstrual Migraine
AbbVie (ABBV) vs. Eli Lilly (LLY): Insights for 2026 Investors
In FY 2025, AbbVie Inc (NYSE:ABBV) reported revenue of nearly $61.2 billion, growing 8.7% from the previous year, with net income around $4.3 billion. Eli Lilly and Co (NYSE:LLY) achieved revenue of approximately $65.2 billion, a significant increase of 45% year-over-year, and net income around $20.6 billion. AbbVie's revenue is heavily reliant on Skyrizi and Rinvoq, while Eli Lilly's GLP-1 drugs, Mounjaro and Zepbound, significantly contribute to its growth. Investors should note the differing risk profiles, with AbbVie facing patent expiration pressures and price reductions affecting certain products, which may influence investment choices.
Read More: AbbVie (ABBV) vs. Eli Lilly (LLY): Insights for 2026 Investors
Altria (MO), Chevron (CVX): 4% Yield Dividend Stocks Insight
Altria (MO) and Chevron (CVX) are part of a three-stock dividend strategy providing a 4% yield and monthly paychecks. Altria recently paid $1.06 per share, holding steady for three quarters, with a share price of $68.08 and a 6.19% dividend yield. AbbVie (ABBV) also contributes, having paid $1.73 per share recently, with its share price at $259.76 and a 2.58% yield. This strategy helps investors receive dividends throughout the year, making it relevant for those seeking consistent income from their investments.
Read More: Altria (MO), Chevron (CVX): 4% Yield Dividend Stocks Insight
AbbVie (ABBV) Presents Lung Cancer Data at WCLC 2026 Conference
AbbVie (ABBV) presented lung cancer data at the World Conference on Lung Cancer (WCLC) 2026, including results for ABBV-1480, which achieved a 90.0% objective response rate in squamous NSCLC and 75.9% in non-squamous NSCLC when combined with platinum-based chemotherapy. Safety data for ABBV-706 showed nausea in 35.8% of patients and grade 3+ pneumonitis or interstitial lung disease in 1.7% of patients.
Read More: AbbVie (ABBV) Presents Lung Cancer Data at WCLC 2026 Conference
AbbVie Expects $12.7 Billion in Neuroscience Sales This Year
AbbVie (ABBV) management projects $12.7 billion in sales from its neuroscience division this year. The company is focusing on expanding its portfolio in this area, which is becoming an increasingly significant part of its operations. This projection reflects AbbVie's strategy to leverage its existing resources and expertise to capitalize on growth in the neuroscience market. For investors, the anticipated earnings could signal positive momentum for AbbVie's stock performance as it strengthens its market position.
Read More: AbbVie Expects $12.7 Billion in Neuroscience Sales This Year
AbbVie (ABBV) Stock Declines Amid Market Uncertainty
AbbVie (ABBV) shares are experiencing a decline today due to market uncertainties affecting investor sentiment. Specific figures regarding the percentage decline or trading volume have not been mentioned, but heightened volatility can often lead to shifts in stock performance. Analysts have noted that fluctuations in broader market trends could be contributing factors to AbbVie's current stock situation. For investors, understanding these market trends is crucial in making informed decisions about holding or trading AbbVie shares.
Read More: AbbVie (ABBV) Stock Declines Amid Market Uncertainty
AbbVie (ABBV) Trims 2026 Profit Forecast Following Apogee Acquisition
AbbVie (ABBV) adjusted its 2026 profit forecast downwards due to the acquisition of Apogee Therapeutics. The company reported second-quarter earnings that exceeded analyst expectations. The updated guidance reflects the financial implications of the acquisition, affecting projected profitability. This revision is significant for investors as it impacts future earnings expectations and may influence AbbVie's stock performance.
Read More: AbbVie (ABBV) Trims 2026 Profit Forecast Following Apogee Acquisition
JPMorgan Recommends Eli Lilly, AbbVie, Danaher as Top Healthcare Stocks
JPMorgan has identified Eli Lilly, AbbVie, and Danaher Corporation as top picks within the healthcare sector. Investors are currently overlooking these stocks, which may present buying opportunities. The recommendation suggests potential growth in these companies as market dynamics shift. This could lead to increased interest and investment in these healthcare stocks, impacting their market performance positively for investors. Eli Lilly (LLY), AbbVie (ABBV), and Danaher (DHR) are highlighted for consideration.
Read More: JPMorgan Recommends Eli Lilly, AbbVie, Danaher as Top Healthcare Stocks
AbbVie (ABBV) Stock May Move 4.2% on July 31 Earnings Report
AbbVie (ABBV) is expected to see a stock price movement of 4.2% following its earnings report scheduled for July 31. This level of volatility suggests that investors are anticipating significant financial metrics from the company. The upcoming earnings could impact investor sentiment and stock performance as market participants digest AbbVie's financial results. This matters for ordinary investors as it indicates possible short-term price fluctuations based on the company's reported performance.
Read More: AbbVie (ABBV) Stock May Move 4.2% on July 31 Earnings Report
AbbVie (ABBV) Reports 2.8% Yield; Baxter (BAX) Cuts Dividend
AbbVie (ABBV) announced a quarterly dividend of $1.73 with a yield of 2.8%, extending its streak of increases since 2013. In contrast, Baxter (BAX) eliminated its dividend, reporting a net income loss of $900 million for FY2025, which disqualifies it from income-focused portfolios. AbbVie's revenue growth from Skyrizi and Rinvoq, at 31% and 23%, respectively, has helped offset losses from Humira and raised guidance for the year. The contrast between the two companies highlights the risks and potential for investors focused on income reliability and growth.
Read More: AbbVie (ABBV) Reports 2.8% Yield; Baxter (BAX) Cuts Dividend
Jefferies Recommends AbbVie (ABBV) as Quality Stock Amid AI Concerns
Jefferies has recommended quality, low-stress stocks amid increasing market volatility related to artificial intelligence investments. They specifically highlight AbbVie (ABBV), predicting nearly 28% compound annual earnings growth for 2026-2027 and a free cash flow yield of 5.2%. AbbVie's first-quarter net revenues reached $15 billion, led by its immunology portfolio of $7.3 billion. The stock has appreciated 25% over the last three months and 37% in the past year, offering a yield of 2.7%. This is important for investors as it suggests stable investment options amidst market fluctuations.
Read More: Jefferies Recommends AbbVie (ABBV) as Quality Stock Amid AI Concerns
AbbVie (ABBV) Hits New 52-Week High; Stock Up 40% Yearly
AbbVie (ABBV) reached a new 52-week high, marking a 40% increase over the past year. Year-to-date, the stock has risen approximately 11%, outperforming the S&P 500's 8% gain. AbbVie trades at less than 18 times its estimated future earnings, below the S&P 500 average of 21. The company recently announced a $10.9 billion acquisition of Apogee Therapeutics, which will enhance its immunology portfolio, suggesting long-term growth potential amidst a strong earnings performance.
Read More: AbbVie (ABBV) Hits New 52-Week High; Stock Up 40% Yearly
AbbVie (ABBV) Acquires Apogee for $10.9 Billion Eczema Drug
AbbVie (ABBV) announced its acquisition of Apogee Therapeutics for $10.9 billion. The focus of this acquisition is Apogee's development of an experimental drug for atopic dermatitis, a type of eczema. This move is significant for AbbVie as it expands its portfolio in dermatological treatments. The transaction underscores the ongoing trend of consolidations in the biotech sector to enhance product pipelines.
Read More: AbbVie (ABBV) Acquires Apogee for $10.9 Billion Eczema Drug
AbbVie (ABBV) Acquires Apogee for $10.9 Billion in Immunology Deal
AbbVie (ABBV) announced its acquisition of Apogee Therapeutics for $10.9 billion, marking its largest buyout in over five years. The $135.11 per share offer represents a 49.49% premium to Apogee's prior closing price, prompting Apogee's shares to surge 48% to $133.77 in premarket trading. The acquisition aims to enhance AbbVie's next-generation immunology pipeline, particularly through the lead drug candidate, zumilokibart. The deal is expected to close in Q3 and contribute positively to AbbVie's adjusted earnings per share by 2032, as pharmaceutical dealmaking accelerates amid patent expirations.
Read More: AbbVie (ABBV) Acquires Apogee for $10.9 Billion in Immunology Deal
Dividend Portfolio Return: $43,770 Annual Income and $7,515 Tax Impact
A $1 million dividend portfolio generates approximately $43,770 annually, subjected to $7,515 in taxes at the 24% bracket. This portfolio includes holdings such as Realty Income (O), Schwab U.S. Dividend Equity ETF (SCHD), and Johnson & Johnson (JNJ). The taxable portion of income is divided into qualified and ordinary income, impacting the total tax liability. The advantage of using a Roth IRA allows the full income to remain untaxed, highlighting the significance of account placement for tax efficiency.
Read More: Dividend Portfolio Return: $43,770 Annual Income and $7,515 Tax Impact
Johnson & Johnson (JNJ) Q1 2026 Revenue Hits $24.06 Billion
Johnson & Johnson (JNJ) reported Q1 2026 revenue of $24.06 billion, representing a 9.9% year-over-year increase, driven by TREMFYA's growth of 68.3% and DARZALEX's increase of 22.5% to $3.96 billion. The company raised its full-year guidance to a midpoint of $100.8 billion. AbbVie (ABBV) also exceeded expectations with Q1 revenue of $15 billion and a year-over-year increase of 12.4%. AbbVie's Skyrizi reached $4.48 billion with a 30.9% increase, offsetting Humira's 38.6% decline.
Read More: Johnson & Johnson (JNJ) Q1 2026 Revenue Hits $24.06 Billion
AbbVie (ABBV) Q3 Earnings Beat Estimates on Immunology Drug Sales
AbbVie (ABBV) reported quarterly earnings that exceeded analysts' expectations, driven by sales from newer immunology drugs that compensated for the decline in Humira's revenue. The company showcased a positive trend as net revenue from immunology reached $2 billion, while Humira sales decreased by 33% to $1.5 billion. This change reflects the ongoing transition to newer therapies, which may bolster AbbVie's market position. The performance indicates potential for recovery and growth, impacting investor sentiment positively.
Read More: AbbVie (ABBV) Q3 Earnings Beat Estimates on Immunology Drug Sales
AbbVie (ABBV) Tops Quarterly Estimates with $15 Billion Revenue
AbbVie (ABBV) reported quarterly revenue of $15 billion, exceeding analyst expectations of $14.72 billion. Profit per share was $2.65, surpassing forecasts of $2.59. Skyrizi sales reached $4.48 billion, growing 30.9%, while Rinvoq saw a 23.3% increase to $2.12 billion. In contrast, Humira's sales decreased by 38.6% to $688 million, missing estimates of $696.5 million. AbbVie also raised its adjusted earnings forecast for the year to $14.08 to $14.28 per share from the previous range of $13.96 to $14.16.
Read More: AbbVie (ABBV) Tops Quarterly Estimates with $15 Billion Revenue
AbbVie (ABBV) Ovarian Cancer Drug Shows 62.7% Response Rate
AbbVie's (ABBV) ovarian cancer drug demonstrated a response rate of 62.7% in clinical trials. This figure is significant as it reflects the drug's potential efficacy and could influence treatment options for patients. The results may impact AbbVie's stock performance in the biopharmaceutical market, considering the ongoing demand for effective oncology therapies. If approved, this drug could enhance AbbVie's position in the oncology segment.
Read More: AbbVie (ABBV) Ovarian Cancer Drug Shows 62.7% Response RateMore Health Care stocks
Frequently asked questions
Is AbbVie Inc. in the S&P 500?
Yes. AbbVie Inc. trades as ABBV and is a member of the S&P 500. The index lists it in the Health Care sector.
What sector is ABBV in?
ABBV sits in the Health Care sector of the S&P 500.
Where can I find the latest ABBV news?
Right here. This page collects recent ABBV news and market analysis. Every story gets an AI summary and a bullish, bearish or neutral tag.
What is AbbVie Inc.'s stock price?
ABBV last traded at about $283.40. Prices move all through the session, so this is the latest quote rather than a live one.
What is AbbVie Inc.'s market cap?
ABBV is worth roughly $500.80B. Market cap is the share price times the number of shares outstanding.
What is ABBV's P/E ratio?
ABBV trades at a trailing P/E ratio of about 77.4. The ratio compares the share price with earnings per share over the past year.